Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
CONCLUSION: Erenumab is an effective once-monthly injectable agent for migraine prevention in patients with chronic or episodic migraine. It is also effective for patients who have previously failed migraine preventive therapy. Erenumab has a favorable adverse effect profile, which may improve patient adherence.
PMID: 30813769 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Garland SG, Smith SM, Gums JG Tags: Ann Pharmacother Source Type: research
More News: Chronic Pain | Clinical Trials | Drugs & Pharmacology | Genetics | Headache | Migraine | Pain | Study | USA Health